Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing
MK Freynhofer, SC Gruber, EL Grove… - Thrombosis and …, 2015 - thieme-connect.com
Platelets are key players in atherothrombosis. Antiplatelet therapy comprising aspirin alone
or with P2Y 12-inhibitors are effective for prevention of atherothrombotic complications …
or with P2Y 12-inhibitors are effective for prevention of atherothrombotic complications …
Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing
S Gruber, E Grove, T Weiss, J Wojta, K Huber… - Thrombosis and …, 2015 - cir.nii.ac.jp
抄録< jats: title> Summary</jats: title>< jats: p> Platelets are key players in atherothrombosis.
Antiplatelet therapy comprising aspirin alone or with P2Y12-inhibitors are effective for …
Antiplatelet therapy comprising aspirin alone or with P2Y12-inhibitors are effective for …
Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing
MK Freynhofer, SC Gruber, EL Grove… - Thrombosis and …, 2015 - pure.au.dk
Platelets are key players in atherothrombosis. Antiplatelet therapy comprising aspirin alone
or with P2Y12-inhibitors are effective for prevention of atherothrombotic complications …
or with P2Y12-inhibitors are effective for prevention of atherothrombotic complications …
[引用][C] Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing.
MK Freynhofer, S Gruber, EL Grove… - THROMBOSIS AND …, 2015 - pure.pmu.ac.at
Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function
testing. — PMU Forschungsportal Zur Hauptnavigation wechseln Zur Suche wechseln Zum …
testing. — PMU Forschungsportal Zur Hauptnavigation wechseln Zur Suche wechseln Zum …
Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing
MK Freynhofer, SC Gruber, EL Grove… - Thrombosis and …, 2015 - pubmed.ncbi.nlm.nih.gov
Platelets are key players in atherothrombosis. Antiplatelet therapy comprising aspirin alone
or with P2Y12-inhibitors are effective for prevention of atherothrombotic complications …
or with P2Y12-inhibitors are effective for prevention of atherothrombotic complications …
Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing
MK Freynhofer, SC Gruber, EL Grove… - Thrombosis and …, 2015 - thieme-connect.com
Platelets are key players in atherothrombosis. Antiplatelet therapy comprising aspirin alone
or with P2Y 12-inhibitors are effective for prevention of atherothrombotic complications …
or with P2Y 12-inhibitors are effective for prevention of atherothrombotic complications …
Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing.
MK Freynhofer, SC Gruber, EL Grove… - Thrombosis and …, 2015 - europepmc.org
Platelets are key players in atherothrombosis. Antiplatelet therapy comprising aspirin alone
or with P2Y12-inhibitors are effective for prevention of atherothrombotic complications …
or with P2Y12-inhibitors are effective for prevention of atherothrombotic complications …
[引用][C] Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing.
MK Freynhofer, S Gruber, EL Grove… - THROMBOSIS AND …, 2015 - pure.pmu.ac.at
Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet
function testing. — PMU Research Portal Skip to main navigation Skip to search Skip to …
function testing. — PMU Research Portal Skip to main navigation Skip to search Skip to …